Impact of physicians' awareness of prostate-specific antigen doubling time (PSADT) on treatment (Tx) decisions in high-risk (HR) biochemically recurrent (BCR) prostate cancer (PC).

Bibliographic Details
Published in:	Journal of Clinical Oncology Vol. 43; pp. 354 - 479
Main Authors:	Morgans, Alicia K., Touya, Maelys, El-Chaar, Nader N., Elsouda, Dina, Ramaswamy, Krishnan, Adejumo, Kelechi L., Gentile, Danielle, Feinberg, Bruce A., Asgarisabet, Parisa, Pathak, Prathamesh, Freedland, Stephen J.
Format:	Journal Article
Published:	American Society of Clinical Oncology 2/10/2025 Supplement5
Online Access:	View this record in EBSCOhost